Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's vac­cine

The Ger­man bil­lion­aires be­hind BioN­Tech have found a new vac­cine project to back.

Through their fam­i­ly of­fice Athos Ser­vice, twin broth­ers Thomas and An­dreas Strüng­mann are lead­ing a $25 mil­lion pri­vate place­ment in­to Switzer­land’s AC Im­mune — which con­cur­rent­ly an­nounced that it’s shelling out $58.7 mil­lion worth of stock to ac­quire Af­firis’ port­fo­lio of ther­a­pies tar­get­ing al­pha-synu­cle­in, in­clud­ing a vac­cine can­di­date, for Parkin­son’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER